Expression and clinical significance of PD-1 in UCEC and its impact on tumor

被引:0
作者
Xing, Fengjuan [1 ]
Yang, Yan [1 ]
Zheng, Wei [2 ]
机构
[1] Qingdao Univ, Dept Pathol, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China
[2] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Gynecol, Yantai, Peoples R China
关键词
endometrial cancer; programmed cell death-1; programmed cell death-ligand 1; CANCER; BLOCKADE;
D O I
10.14715/cmb/2023.69.5.26
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed death 1 (PD-1) plays an important role in the immune escape, occurrence and development of tumors by inhibiting the function of immune cells. However, its prognostic value in uterine corpus endometrial carcinoma (UCEC) and its impact on the tumor microenvironment remain to be further explored. Transcriptional datasets were retrieved from the GEPIA, TIMER and TCGA databases. "edgeR" package was used for the identification of differentially expressed genes (DEGs) between two groups of patients (PD1-high and PD1-low group). Gene set enrichment analysis (GSEA) was performed to identify underlying pathways between betweenPD1-high and PD1-low groups functioning in UCEC. Gene Correlation Analysis was used to further confirm the associations of PD1 expression with T-cell-related genes. Cytoscape software was used to identify hub genes in DEGs. Kaplan-Meier analysis was performed to validate the prognostic value of hub genes. Mutational characteristics of UCEC patients according to PD1 levels were depicted and analyzed. We found that the transcriptional expression of the PD1 gene in UCEC tumor tissues markedly increased in cohorts from the GEPIA and TCGA databases. PD1 expression was negatively correlated with gene signatures associated with the T-cell receptor signaling pathway and primary immunodeficiency. GESA confirmed that PD1 expression was negatively correlated with gene signatures associated with the T-cell receptor signaling pathway. T-cell receptor complex-related genes, ZAP70, TRAC, CD3D, CD3E, CD8A, TRBC2, TRBV28 and CD247, showed significant positive associations with PD1 expression. The results of the Kaplan-Meier OS analysis indicated that PD1, TIGIT, FASLG, ICOS and TNFRSF9 are the protective factor for patients with UCEC. The top 5 genes of mutations in the low expression group, included PTEN (56%), PIK3CA (43%), TP53 (41%), TTN (39%), and ARID1A (37%). The genes with a higher proportion of mutations in the PD1high group are PTEN (67%), TTN (62%), PIK3CA (53%), ARID1A (52%), and MUC16 (12%). The prognosis of UCEC patients with PD1 overexpression phenotype is worse than that of the PD1 low group, which is due to the involvement of the PD1 gene in the T-cell receptor signaling pathway. This study provides a further theoretical basis and reference for targeted therapy against PD1.
引用
收藏
页码:168 / 173
页数:6
相关论文
共 28 条
  • [1] Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
    Amatore, Florent
    Gorvel, Laurent
    Olive, Daniel
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (02) : 141 - 150
  • [2] Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
    Ayakannu, Thangesweran
    Taylor, Anthony H.
    Konje, Justin C.
    [J]. HISTOCHEMISTRY AND CELL BIOLOGY, 2021, 156 (05) : 449 - 460
  • [3] 4-1 BB agonists: multi-potent potentiators of tumor immunity
    Bartkowiak, Todd
    Curran, Michael A.
    [J]. FRONTIERS IN ONCOLOGY, 2015, 5
  • [4] [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
  • [5] Breast Cancer Expert Committee of National Cancer Quality Control Center, 2020, Zhonghua Zhong Liu Za Zhi, V42, P781, DOI 10.3760/cma.j.cn112152-20200817-00747
  • [6] PTEN: Tumor Suppressor and Metabolic Regulator
    Chen, Chien-Yu
    Chen, Jingyu
    He, Lina
    Stiles, Bangyan L.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [7] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [8] ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State
    Chudnovsky, Yakov
    Kim, Dohoon
    Zheng, Siyuan
    Whyte, Warren A.
    Bansal, Mukesh
    Bray, Mark-Anthony
    Gopal, Shuba
    Theisen, Matthew A.
    Bilodeau, Steve
    Thiru, Prathapan
    Muffat, Julien
    Yilmaz, Omer H.
    Mitalipova, Maya
    Woolard, Kevin
    Lee, Jeongwu
    Nishimura, Riko
    Sakata, Nobuo
    Fine, Howard A.
    Carpenter, Anne E.
    Silver, Serena J.
    Verhaak, Roel G. W.
    Califano, Andrea
    Young, Richard A.
    Ligon, Keith L.
    Mellinghoff, Ingo K.
    Root, David E.
    Sabatini, David M.
    Hahn, William C.
    Chheda, Milan G.
    [J]. CELL REPORTS, 2014, 6 (02): : 313 - 324
  • [9] Structural basis of assembly of the human T cell receptor-CD3 complex
    Dong, De
    Zheng, Lvqin
    Lin, Jianquan
    Zhang, Bailing
    Zhu, Yuwei
    Li, Ningning
    Xie, Shuangyu
    Wang, Yuhang
    Gao, Ning
    Huang, Zhiwei
    [J]. NATURE, 2019, 573 (7775) : 546 - +
  • [10] TIGIT as an emerging immune checkpoint
    Harjunpaa, H.
    Guillerey, C.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 200 (02) : 108 - 119